Aytu BioPharma (AYTU) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Serina Therapeutics (SER) over the past year, gaining 32.3% versus a loss of 71.9%. Over five years, AYTU leads with a -93.2% price change compared with -95.6% for SER. Serina Therapeutics is the larger company by market cap ($29.8 million vs $28.9 million), about 1.0 times the size.
Aytu BioPharma converts more of its revenue into profit, with a net margin of -24.8% versus -14755.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | SER |
|---|---|---|
| Share price | $2.66 | $1.12 |
| Market cap | $28.91M | $29.76M |
| 1-day change | 0.00% | -6.67% |
| YTD return | +2.31% | -41.45% |
| 1-year return | +32.34% | -71.93% |
| 5-year return | -93.21% | -95.64% |
| Forward P/E | 17.16 | — |
| EPS (TTM) | $-1.78 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $57.57M | $130.00K |
| Revenue growth (YoY) | -13.27% | +132.14% |
| Net income (latest FY) | $-14.25M | $-19.18M |
| Gross margin | 63.95% | — |
| Operating margin | -14.44% | -18478.46% |
| Net margin | -24.76% | -14755.38% |
| 52-week high | $3.07 | $4.26 |
| 52-week low | $1.75 | $1.06 |
| Distance from 52-week high | -13.36% | -73.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +263.53% | +748.21% |
| Average volume | 141.18K | 68.98K |
| Shares outstanding | 10.87M | 26.57M |
| Employees | 75 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed SER by 104.3 percentage points over the past year.
- Aytu BioPharma is more profitable, keeping -24.8 cents of every revenue dollar as net income versus -14755.4 cents for Serina Therapeutics.
- Serina Therapeutics grew revenue faster in its latest fiscal year (+132.14% vs -13.27%).
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
AYTU vs SER FAQ
Which is bigger, Aytu BioPharma or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $28.91M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, AYTU or SER?
AYTU returned +32.34% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.